VJVirtual | Blastic plasmacytoid dendritic cell neoplasms: current and future treatment options
Naveen Pemmaraju
• 15 May 2020
Naveen Pemmaraju, MD, of the MD Anderson Cancer Center, Houston, TX, discusses novel treatments that have been developed against blastic plasmacytoid dendritic cell neoplasms (BPDCP), a rare and aggressive disease affecting skin, bone marrow and lymph nodes. Tagraxofusp, a CD123 targeted therapy has gained FDA approval for BPDCN as CD123 (encoding IL3RA) is often overexpressed in these patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
